Daraxonrasib
-
healthPancreatic Cancer Pill Doubles Survival, Canada Trial Eyed
A daily pill, daraxonrasib, doubles survival for pancreatic cancer patients. Canadian doctors seek clinical trials.
-
healthNew Pancreatic Cancer Pill Shows Promise, 90% of Patients Respond in Early Trial
An experimental daily pill, daraxonrasib, shows a 90% disease control rate in advanced pancreatic cancer patients during early-stage clinical trials.
-
healthPan-RAS Inhibitor Shows Survival Gain in Pancreatic Cancer
Daraxonrasib, a pan-RAS inhibitor, demonstrated improved survival and tumor control in advanced pancreatic cancer in early trials.
-
healthExperimental Pancreatic Cancer Drug Daraxonrasib Nears Approval, Shows Surge in Demand
Daraxonrasib nearly doubles survival in trials, now in early access amid high demand before full FDA approval.
-
healthHope for Pancreatic Cancer Patients as New Drug Shows Promise
Revolution Medicines' daraxonrasib doubles survival in advanced pancreatic cancer, sparking patient demand and FDA compassionate use access.
-
healthBen Sasse Reports Significant Tumor Reduction with Experimental Pancreatic Cancer Drug
Former Senator Ben Sasse details substantial tumor shrinkage and pain reduction from an experimental pancreatic cancer therapy, daraxonrasib, showing promising results in clinical trials.